|
Accueil > Actualité
Roche: positive topline results to treat hypertension
(CercleFinance.com) - Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease.
The study also met key secondary endpoints showing consistent and sustained reductions of SBP at six months supporting quarterly or biannual dosing. In addition, the study showed that zilebesiran was associated with a potent and durable reduction of serum AGT levels through month six while demonstrating an encouraging safety and tolerability profile. " These early results indicate the potential for zilebesiran to achieve sustained blood pressure reduction with quarterly or biannual dosing, " said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. Copyright (c) 2023 CercleFinance.com. All rights reserved. |
23/05/2025 17:40
UbisoftBarclays détient moins de 5% du capital 23/05/2025 17:10 Legrandla société FIL détient plus de 5% du capital 23/05/2025 17:02 PublicisBlackRock détient plus de 5% des droits de votes 23/05/2025 16:50 AlstomBlackRock sous les 5% du capital & des votes 23/05/2025 16:00 J&Jprésentera 70 résumés lors du congrès de l'ASCO 23/05/2025 15:52 Generalien recul avec une dégradation d'analyste Tous les articles sociétés |
